Form 4: Imunon Director Acquires Options in Company Stock

Donald P. Braun, a director of Imunon, Inc., acquired options to purchase 3,500 shares of Imunon common stock at an exercise price of $0.86 on March 15, 2024.

Summary

• On March 15, 2024, Donald P. Braun, a director of Imunon, Inc., acquired options to purchase 3,500 shares of Imunon, Inc. common stock.
• The exercise price of these options is $0.86 per share.
• The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• The options expire on March 15, 2034.
• Following this transaction, Braun directly owns 19,930 shares of Imunon common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine insider transaction. The acquisition of options by a director is generally viewed as a positive sign, but it's a small transaction.

Positives

• A director's acquisition of options can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates

Keywords

Imunon, Director, Options, Stock, Acquisition, IMNN, Beneficial Ownership, Form 4